iA Global Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.8M Sell
30,915
-6,770
-18% -$3.16M 0.2% 105
2025
Q4
$17.1M Buy
37,685
+1,843
+5% +$794K 0.22% 98
2025
Q3
$14M Buy
35,842
+685
+2% +$286K 0.19% 97
2025
Q2
$15.7M Sell
35,157
-167
-0.5% -$77K 0.24% 83
2025
Q1
$17.1M Sell
35,324
-5,538
-14% -$2.58M 0.29% 68
2024
Q4
$16.5M Sell
40,862
-404
-1% -$187K 0.29% 67
2024
Q3
$19.2M Sell
41,266
-844
-2% -$405K 0.34% 61
2024
Q2
$19.7M Sell
42,110
-696
-2% -$302K 0.38% 56
2024
Q1
$17.9M Sell
42,806
-12,142
-22% -$5.13M 0.37% 55
2023
Q4
$22.4M Buy
54,948
+5,403
+11% +$2M 0.52% 45
2023
Q3
$17.2M Buy
49,545
+10,146
+26% +$3.55M 0.46% 53
2023
Q2
$13.9M Buy
+39,399
New +$13.3M 0.37% 59

Other funds holding VRTX

iA Global Asset Management's VRTX Position: Q1 2026 in Review

iA Global Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 18% in Q1 2026, selling an estimated $3.16M and leaving 30,915 shares worth $13.8M. The position accounts for 0.2% of the portfolio, ranked #105.

iA Global Asset Management first reported a position in VRTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $22.4M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • iA Global Asset Management held 30,915 shares of Vertex Pharmaceuticals worth $13.8M as of Q1 2026.
  • iA Global Asset Management sold 6,770 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.16M.
  • Vertex Pharmaceuticals made up 0.2% of iA Global Asset Management's portfolio in Q1 2026, its #105 holding.
  • iA Global Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • iA Global Asset Management's Vertex Pharmaceuticals position peaked at $22.4M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on iA Global Asset Management's 13F filing for Q1 2026, filed 23 Apr 2026.